A 28-year-old woman with poorly controlled asthma presents to the emergency department with acute dyspnea, inability to speak in complete sentences, and use of accessory muscles. Spirometry shows the flow-volume loop pattern marked **A** in the diagram, with FEV1

Question

A 28-year-old woman with poorly controlled asthma presents to the emergency department with acute dyspnea, inability to speak in complete sentences, and use of accessory muscles. Spirometry shows the flow-volume loop pattern marked **A** in the diagram, with FEV1 <25% predicted and a severely concave expiratory limb. She is alert but exhausted, SpO₂ 88% on room air, HR 125/min, RR 32/min. Which of the following is the MOST appropriate immediate pharmacological intervention for this life-threatening exacerbation?

Accepted Answer

B. High-flow oxygen, continuous nebulized salbutamol, ipratropium bromide, systemic corticosteroids, and IV magnesium sulfate 2 g over 20 minutes. ## Why Option 1 is correct

The flow-volume loop pattern marked **A** — FEV1 <25% predicted with severely concave expiratory limb — is a RED-FLAG for life-threatening asthma exacerbation per GINA 2024 and BTS/SIGN guidelines. This patient meets multiple criteria for life-threatening severity: SpO₂ <92%, FEV1 <25% predicted, exhaustion, inability to complete sentences, and poor respiratory effort. GINA 2024 and the 3Mg trial (Lancet 2013) mandate immediate aggressive therapy: (1) HIGH-FLOW OXYGEN targeting SpO₂ 93–95% (avoiding over-oxygenation); (2) CONTINUOUS NEBULIZED SALBUTAMOL 5 mg every 20 minutes × 3, then continuous, PLUS IPRATROPIUM BROMIDE 500 µg nebulized every 20 minutes for the first hour (added anticholinergic benefit in severe exacerbations); (3) SYSTEMIC CORTICOSTEROIDS (prednisolone 40–50 mg or IV methylprednisolone) as early as possible; and (4) IV MAGNESIUM SULFATE 2 g over 20 minutes — robust evidence from the 3Mg and MAGNETIC trials for benefit in severe exacerbations refractory to initial therapy, particularly when FEV1 <25%, via smooth-muscle relaxation through calcium-channel blockade. This is the only option that reflects guideline-concordant management of life-threatening asthma.

## Why each distractor is wrong

- **Option 2**: Single-dose salbutamol is insufficient for FEV1 <25%; prednisolone 20 mg is subtherapeutic (guidelines recommend 40–50 mg); omits ipratropium and magnesium sulfate, which are critical in life-threatening exacerbations. SpO₂ target >95% risks worsening outcomes (GINA recommends 93–95%).
- **Option 3**: Intermittent salbutamol every 4 hours is dangerously inadequate for life-threatening exacerbation (requires continuous or every-20-minute dosing); inhaled beclomethasone is too slow and weak (systemic corticosteroids required); 2-hour observation is inappropriate — this patient requires ICU admission and continuous monitoring.
- **Option 4**: IV theophylline is not recommended in acute severe asthma (narrow therapeutic index, no proven benefit over beta-agonists, risk of arrhythmia); dexamethasone 8 mg daily is suboptimal compared to prednisolone 40–50 mg; omits magnesium sulfate and ipratropium.

**High-Yield:** FEV1 <25% predicted with concave expiratory loop = life-threatening asthma requiring continuous salbutamol + ipratropium + IV magnesium sulfate + high-dose corticosteroids + ICU monitoring and preparation for intubation.

[cite: GINA 2024; BTS/SIGN Asthma Guideline; 3Mg trial Lancet 2013]

Answer

A. Oxygen to maintain SpO₂ >95%, single-dose salbutamol nebulization, and oral prednisolone 20 mg

Answer

C. Oxygen, intermittent salbutamol every 4 hours, inhaled beclomethasone, and observation for 2 hours

Answer

D. Oxygen, IV theophylline, and oral dexamethasone 8 mg daily for 5 days

Explanation

Why Option 1 is correct

Why each distractor is wrong

Practice similar questions